Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 80
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00122564 | Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers | ||
| NCT00291590 | Diabetes Health Enhancement Program to Improve Health of People With Diabetes | ||
| NCT00211224 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | ||
| NCT00268593 | Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | ||
| NCT00176059 | Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients | ||
| NCT00527761 | Taxotere/Temodar/Cisplatin Study in Melanoma Patients | ||
| NCT00198237 | Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | ||
| NCT00196651 | HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection | ||
| NCT00822471 | Feasibility and Impact of "ABCs of Diabetes" Self-Management Education Program at an Urban Public Library | ||
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | ||
| NCT00216008 | Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation. | ||
| NCT00186420 | Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation | ||
| NCT00193427 | Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer | ||
| NCT00206505 | Neoadjuvant Taxotere | ||
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | ||
| NCT00240747 | Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients | ||
| NCT00190411 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | ||
| NCT01035528 | Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) | ||
| NCT03004001 | Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome | ||
| NCT00193128 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | ||
| NCT00221845 | Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients | ||
| NCT00189657 | 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer | ||
| NCT00194740 | Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer | ||
| NCT00193115 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | ||
| NCT00270894 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | ||
| NCT00193050 | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | ||
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer | ||
| NCT00194558 | Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care | ||
| NCT00003257 | Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer | ||
| NCT00118053 | Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer | ||
| NCT01652820 | Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer | ||
| NCT00149175 | Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment | ||
| NCT00318903 | Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer | ||
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | ||
| NCT00148070 | Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer | ||
| NCT00193024 | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer | ||
| NCT00113347 | Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | ||
| NCT00318890 | Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck | ||
| NCT00280735 | Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC | ||
| NCT00068341 | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer | ||
| NCT00170378 | The Use of Low Molecular Weight Heparin in Traumatic Brain Injury | ||
| NCT00005800 | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | ||
| NCT00288444 | Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | ||
| NCT00210249 | Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment | ||
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | ||
| NCT00066885 | Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer | ||
| NCT00165464 | Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer | ||
| NCT00257348 | Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer | ||
| NCT00118508 | The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study) | ||
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer |
